11/21/2024

Janusmed kön och genus

Janusmed kön och genus – Linezolid Actavis

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
C C
C C

Linezolid

Linezolid

Klass : C

Visa all info

Skriv ut

Kontakta oss

  1. Humphreys H, Fitzpatick F, Harvey BJ. Gender differences in rates of carriage and bloodstream infection caused by methicillin-resistant Staphylococcus aureus: are they real, do they matter and why?. Clin Infect Dis. 2015;61(11):1708-14.

  2. Westgeest AC, Lambregts MMC, Ruffin F, Korn RE, Webster ME, Kair JL et al. Female Sex and Mortality in Patients with Staphylococcus aureus Bacteremia: A Systematic Review and Meta-analysis. JAMA Netw Open. 2024;7(2):e240473.

  3. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - Zyvox (linezolid). Drugs@FDA [www]. [updated 2000-04-18, cited 2024-06-25].

  4. Sisson TL, Jungbluth GL, Hopkins NK. Age and sex effects on the pharmacokinetics of linezolid. Eur J Clin Pharmacol. 2002;57(11):793-7.

  5. Burkhardt O, Borner K, von der Höh N, Köppe P, Pletz MW, Nord CE et al. Single- and multiple-dose pharmacokinetics of linezolid and co-amoxiclav in healthy human volunteers. J Antimicrob Chemother. 2002;50(5):707-12.

  6. Abe S, Chiba K, Cirincione B, Grasela TH, Ito K, Suwa T. Population pharmacokinetic analysis of linezolid in patients with infectious disease: application to lower body weight and elderly patients. J Clin Pharmacol. 2009;49(9):1071-8.

  7. Meagher AK, Forrest A, Rayner CR, Birmingham MC, Schentag JJ. Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrob Agents Chemother. 2003;47(2):548-53.

  8. Whitehouse T, Cepeda JA, Shulman R, Aarons L, Nalda-Molina R, Tobin C et al. Pharmacokinetic studies of linezolid and teicoplanin in the critically ill. J Antimicrob Chemother. 2005;55(3):333-40.

  9. Food and Drug Administration (FDA). Drug label - Zyvox (linezolid). Drugs@FDA [www]. [updated 2024-06-27, cited 2024-08-15].

  10. Zyvoxid (linezolid). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2024-06-20, cited 2024-08-15]

  11. Food and Drug Administration (FDA). Medical review - Zyvox (linezolid). Drugs@FDA [www]. [updated 2001-11-20, cited 2024-06-25].

  12. Tsutsumi T, Imai S, Kashiwagi H, Sato Y, Sugawara M, Takekuma Y. Investigation of the risk factors of vomiting during linezolid therapy: a retrospective observational study. Eur J Clin Pharmacol. 2022;78(2):279-286.

  13. Wasserman S, Brust JCM, Abdelwahab MT, Little F, Denti P, Wiesner L et al. Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study. J Antimicrob Chemother. 2022;77(4):1146-1154.

  14. Natsumoto B, Yokota K, Omata F, Furukawa K. Risk factors for linezolid-associated thrombocytopenia in adult patients. Infection. 2014;42(6):1007-12.

  15. Niwa T, Suzuki A, Sakakibara S, Kasahara S, Yasuda M, Fukao A et al. Retrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy. Clin Ther. 2009;31(10):2126-33.

  16. Cui D, Hu X, Shi L, Wang D, Chen G. Linezolid-related adverse effects in the treatment of rifampicin resistant tuberculosis: a retrospective study. J Chemother. 2023;35(5):404-410.

  17. Mao Y, Dai D, Jin H, Wang Y. The risk factors of linezolid-induced lactic acidosis: A case report and review. Medicine (Baltimore). 2018;97(36):e12114.

  1. Humphreys H, Fitzpatick F, Harvey BJ. Gender differences in rates of carriage and bloodstream infection caused by methicillin-resistant Staphylococcus aureus: are they real, do they matter and why?. Clin Infect Dis. 2015;61(11):1708-14.
  2. Westgeest AC, Lambregts MMC, Ruffin F, Korn RE, Webster ME, Kair JL et al. Female Sex and Mortality in Patients with Staphylococcus aureus Bacteremia: A Systematic Review and Meta-analysis. JAMA Netw Open. 2024;7(2):e240473.
  3. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - Zyvox (linezolid). Drugs@FDA [www]. [updated 2000-04-18, cited 2024-06-25].
  4. Sisson TL, Jungbluth GL, Hopkins NK. Age and sex effects on the pharmacokinetics of linezolid. Eur J Clin Pharmacol. 2002;57(11):793-7.
  5. Burkhardt O, Borner K, von der Höh N, Köppe P, Pletz MW, Nord CE et al. Single- and multiple-dose pharmacokinetics of linezolid and co-amoxiclav in healthy human volunteers. J Antimicrob Chemother. 2002;50(5):707-12.
  6. Abe S, Chiba K, Cirincione B, Grasela TH, Ito K, Suwa T. Population pharmacokinetic analysis of linezolid in patients with infectious disease: application to lower body weight and elderly patients. J Clin Pharmacol. 2009;49(9):1071-8.
  7. Meagher AK, Forrest A, Rayner CR, Birmingham MC, Schentag JJ. Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrob Agents Chemother. 2003;47(2):548-53.
  8. Whitehouse T, Cepeda JA, Shulman R, Aarons L, Nalda-Molina R, Tobin C et al. Pharmacokinetic studies of linezolid and teicoplanin in the critically ill. J Antimicrob Chemother. 2005;55(3):333-40.
  9. Food and Drug Administration (FDA). Drug label - Zyvox (linezolid). Drugs@FDA [www]. [updated 2024-06-27, cited 2024-08-15].
  10. Zyvoxid (linezolid). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2024-06-20, cited 2024-08-15]
  11. Food and Drug Administration (FDA). Medical review - Zyvox (linezolid). Drugs@FDA [www]. [updated 2001-11-20, cited 2024-06-25].
  12. Tsutsumi T, Imai S, Kashiwagi H, Sato Y, Sugawara M, Takekuma Y. Investigation of the risk factors of vomiting during linezolid therapy: a retrospective observational study. Eur J Clin Pharmacol. 2022;78(2):279-286.
  13. Wasserman S, Brust JCM, Abdelwahab MT, Little F, Denti P, Wiesner L et al. Linezolid toxicity in patients with drug-resistant tuberculosis: a prospective cohort study. J Antimicrob Chemother. 2022;77(4):1146-1154.
  14. Natsumoto B, Yokota K, Omata F, Furukawa K. Risk factors for linezolid-associated thrombocytopenia in adult patients. Infection. 2014;42(6):1007-12.
  15. Niwa T, Suzuki A, Sakakibara S, Kasahara S, Yasuda M, Fukao A et al. Retrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy. Clin Ther. 2009;31(10):2126-33.
  16. Cui D, Hu X, Shi L, Wang D, Chen G. Linezolid-related adverse effects in the treatment of rifampicin resistant tuberculosis: a retrospective study. J Chemother. 2023;35(5):404-410.
  17. Mao Y, Dai D, Jin H, Wang Y. The risk factors of linezolid-induced lactic acidosis: A case report and review. Medicine (Baltimore). 2018;97(36):e12114.